Cargando…

Effectiveness of Tocilizumab in Patients with Severe or Critical Lung Involvement in COVID-19: A Retrospective Study

Introduction: Acute lung injury is associated with dysfunctional immune response to SARS-CoV-2. This leads to CRS, which require immunomodulatory treatments aiming to limit the excessive production of cytokines. The literature so far indicates the effectiveness of tocilizumab in patients with COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chober, Daniel, Aksak-Wąs, Bogusz, Bobrek-Lesiakowska, Katarzyna, Budny-Finster, Anna, Hołda, Ewa, Mieżyńska-Kurtycz, Joanna, Jamro, Grzegorz, Parczewski, Miłosz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101084/ https://www.ncbi.nlm.nih.gov/pubmed/35566412 http://dx.doi.org/10.3390/jcm11092286

Ejemplares similares

Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study
por: Chober, Daniel, et al.
Publicado: (2022)

Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study
por: Chober, Daniel, et al.
Publicado: (2022)

Phylodynamic Dispersal of SARS-CoV-2 Lineages Circulating across Polish–German Border Provinces
por: Serwin, Karol, et al.
Publicado: (2022)

Factors Influencing Immune Restoration in People Living with HIV/AIDS
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Protective Effect of HLA-B*5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland
por: Leszczyszyn-Pynka, Magdalena, et al.
Publicado: (2015)

Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2021)

Correction: Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Septic Shock Induced by Vibrio Vulnificus in Northern Poland, a Case Report
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2021)

Hepatotropic Properties of SARS-CoV-2—Preliminary Results of Cross-Sectional Observational Study from the First Wave COVID-19 Pandemic
por: Wiśniewska, Hanna, et al.
Publicado: (2021)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
por: Huang, Edmund, et al.
Publicado: (2021)

Transmitted HIV drug resistance and subtype patterns among blood donors in Poland
por: Parczewski, Miłosz, et al.
Publicado: (2021)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
por: Hafez, Wael, et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2014)

Temporal increase in HIV-1 non-R5 tropism frequency among antiretroviral-naive patients from northern Poland
por: Parczewski, Milosz, et al.
Publicado: (2014)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients
por: Fisher, Matthew J., et al.
Publicado: (2021)

Patient Nutrition and Probiotic Therapy in COVID-19: What Do We Know in 2021?
por: Hawryłkowicz, Viktoria, et al.
Publicado: (2021)

IgA-Based Secretory Response in Tears of COVID-19 Patients: A Potential Biomarker of Pro-Inflammatory State in Course of SARS-CoV-2 Infection
por: Niedźwiedź, Anna, et al.
Publicado: (2022)

Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland
por: Leszczyszyn-Pynka, Magdalena, et al.
Publicado: (2016)

The temporal increase in HIV-1 non-R5 tropism frequency among newly diagnosed patients from northern Poland is associated with clustered transmissions
por: Parczewski, Miłosz, et al.
Publicado: (2015)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022)

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020)

Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study
por: Radulescu, Amanda, et al.
Publicado: (2022)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2012)

Influence of Physical Fitness and Attention Level on Academic Achievements of Female and Male Military Academy Cadets in Poland
por: Jamro, Dariusz, et al.
Publicado: (2021)

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Experience
por: Zeair, Samir, et al.
Publicado: (2019)

Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study
por: Hu, Qin, et al.
Publicado: (2021)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
por: Zeng, Jia, et al.
Publicado: (2020)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Molecular Analysis of the Heterakis dispar Population in Domestic Geese Based on the ITS1-5.8rRNA-ITS2 Fragment
por: Bobrek, Kamila, et al.
Publicado: (2022)

COVID-19-Associated Encephalopathy—Case Series and Clinical Considerations
por: Udzik, Jakub, et al.
Publicado: (2022)

Clinical Predictors of Response to Tocilizumab: A Retrospective Multicenter Study
por: Ercan, Selin, et al.
Publicado: (2022)

Phytochemical Molecules from the Decarboxylation of Gomphrenins in Violet Gomphrena globosa L.—Floral Infusions from Functional Food
por: Drobnicka, Natalia, et al.
Publicado: (2020)

Evaluating Ocular Symptoms and Tear Film Cytokine Profiles in Symptomatic COVID-19 Patients
por: Niedźwiedź, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gvp8hd0llqd22ju32nha94smsf